Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02058758 · ClinicalTrials.gov registry record

Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer

A clinical trial, sponsored by University of Minnesota.

Completed
Registry status
80
Enrollment target

NCT02058758: Completed study, sponsored by University of Minnesota.

NCT02058758 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02058758 has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
80 participants
Enrollment target

Study Summary

Contrast-enhanced magnetic resonance imaging (CE-MRI) is now established as the most accurate non-invasive imaging modality for characterizing breast cancer. CE-MRI has a very high sensitivity because the intravenous MR contrast agent highlights regions with increased vascularization and vascular permeability compared to normal breast tissues and benign lesions.

Primary Outcome

Demonstration of the feasibility of using SLIM-based techniques for acquiring spectoscopic data for quantifying choline and other metabolites in breast cancer.

Interventions

  • DEVICE Magnetic Resonance Imaging

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2014-03-01
Est. Completion 2019-09-01
University of Minnesota

966 total trials

What the finished NCT02058758 record still lists

NCT02058758 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Magnetic Resonance Imaging is the first listed.

NCT02058758 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02058758 about?

NCT02058758 is a clinical study titled "Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer". Contrast-enhanced magnetic resonance imaging (CE-MRI) is now established as the most accurate non-invasive imaging modality for characterizing breast cancer. CE-MRI has a very high sensitivity because the intravenous MR contrast agent highlights regions with increased vascularization and vascular pe...

What is the current status of trial NCT02058758?

This trial is currently completed. The enrollment target is 80 participants. The study started on 2014-03-01. Estimated completion is 2019-09-01.

What interventions are being tested in trial NCT02058758?

The interventions under investigation include: Magnetic Resonance Imaging (DEVICE).

Who is sponsoring clinical trial NCT02058758?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02058758, the US trial registry maintained by the National Library of Medicine. NCT02058758 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.